[11c]az1419 3391
Preclinical
AstraZeneca[11c]az1419 3391 is one of 6 therapeutic programs targeting Advanced Solid Malignancies. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
7 competitors in Advanced Solid Malignancies
#DrugCompanyPhaseTrials
1DATROWAY
Daiichi SankyoPreclinical
Faslodex
FFresenius Kabi Oncology Ltd.
Preclinical
Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Trastuzumab Deruxtecan
AstraZenecaPreclinical
AZD9574
AstraZenecaPreclinical
[11c]az1419 3391
AstraZenecaPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Malignancies1 trial
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for [11c]az1419 3391. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]
- Company